Reports Q2 revenue EUR 158.05M vs. EUR 36M last year. “With the robust global uptake of YORVIPATH and with TransCon CNP under U.S. FDA priority review, Ascendis is on the verge of bringing our third high-value medicine to patients and substantially transforming our financial profile,” said Jan Mikkelsen, Ascendis Pharma’s (ASND) President and Chief Executive Officer. “We expect our engine for future innovation to drive continued momentum as we aim to address unmet medical need in endocrine rare diseases and other large indications for years to come on our path to fulfilling Vision 2030.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma Reports Strong Q2 2025 Results and Advances Key Therapies
- Ascendis Pharma’s Clinical Trial Update: Implications for Investors
- Bullish Outlook on Ascendis Pharma: FDA Approval and Anticipated Product Launches Drive Buy Rating
- Buy Rating for Ascendis Pharma Driven by Skytrofa’s FDA Approval and Market Potential
- Ascendis Pharma Gains FDA Approval for Adult Growth Hormone Therapy